Omnicell, Inc.

Report azionario NasdaqGS:OMCL

Capitalizzazione di mercato: US$2.0b

Omnicell Crescita futura

Criteri Future verificati 3/6

Si prevede che Omnicell aumenterà gli utili e i ricavi rispettivamente del 36.2% e 4.3% all'anno, mentre si prevede che l'EPS crescerà del 35.7% all'anno.

Informazioni chiave

36.2%

Tasso di crescita degli utili

35.74%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili16.0%
Tasso di crescita dei ricavi4.3%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento01 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento dell'analisi • May 01

OMCL: New Product Cycle Will Reset Expectations And Support Higher Future Earnings Multiple

Analysts have reset their view on Omnicell, with the consolidated fair value estimate moving from $49.00 to $55.00. This reflects updated assumptions on discount rate, growth, margins and future P/E, alongside recent price target hikes and rating changes across the Street.
Aggiornamento dell'analisi • Apr 16

OMCL: New Product Cycle Will Drive Next Cabinet Super Cycle

Narrative Update on Omnicell Analysts now see a slightly lower blended price target for Omnicell, with recent moves spanning a $14 cut at one firm and a $10 increase at another. They are weighing a new product cycle against differing views on execution and risk.
Aggiornamento dell'analisi • Apr 01

OMCL: Cabinet Replacement Cycle Will Drive Future Super Cycle Repricing

Narrative Update on Omnicell The updated analyst price target for Omnicell has shifted by $14 as analysts balance recent upgrades tied to a new product cycle and cabinet replacement opportunity against a lower target from one firm, while keeping the model's fair value estimate steady at $49. Analyst Commentary Recent research on Omnicell presents a mixed picture, with some firms highlighting upside linked to a new product cycle and cabinet replacement opportunity, while more cautious voices are resetting expectations and price targets.
Aggiornamento dell'analisi • Mar 18

OMCL: Cabinet Replacement Cycle Will Drive Future Risk Reward Repricing

Analysts have trimmed the Omnicell fair value estimate from $50.00 to $49.00, reflecting slightly softer assumptions for revenue growth and profit margins, even as they factor in a higher future P/E multiple supported by recent upgrades tied to the new product cycle and cabinet refresh story. Analyst Commentary Recent Street research on Omnicell has been mixed, with some firms trimming price targets while others turn more constructive on the new product cycle and cabinet refresh opportunity.
Aggiornamento dell'analisi • Mar 04

OMCL: Cabinet Replacement Cycle Will Drive Future Medication Management Upside

Analysts have adjusted their Omnicell price target by $14, reflecting mixed research that includes both target cuts and upgrades related to expectations around the new product cycle and potential cabinet replacement demand. Analyst Commentary Bullish Takeaways Bullish analysts see the new Titan XT cabinets as a key product that could support higher long term growth expectations if hospitals move ahead with planned cabinet replacements.
Aggiornamento dell'analisi • Feb 18

OMCL: Cabinet Refresh Cycle Will Support Future Medication Management Upside

Analysts have nudged their fair value estimate for Omnicell higher from $51.50 to about $57.43, citing updated views on its product cycle and cabinet refresh opportunity as reflected in recent research. Analyst Commentary Recent research coverage on Omnicell reflects a mix of optimism around the new product cycle and cabinet refresh, alongside some restraint on how quickly that opportunity may translate into value.
Articolo di analisi • Feb 12

Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge

The Omnicell, Inc. ( NASDAQ:OMCL ) share price has softened a substantial 26% over the previous 30 days, handing back...
Aggiornamento dell'analisi • Feb 04

OMCL: Cabinet Replacement Cycle Could Drive Upside In Concentrated Market

Analysts have raised their fair value estimate for Omnicell to US$63 from US$55, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. This change is supported by recent positive research on the potential impact of the Titan XT cabinet cycle and competitive wins.
Aggiornamento dell'analisi • Jan 21

OMCL: Cabinet Replacement Cycle Will Shape Future Risk Reward Balance

Narrative Update on Omnicell The analyst price target for Omnicell has moved from $43 to $50 as analysts point to potential cabinet replacement demand and the Titan XT launch as key drivers for expected improvements in sales, earnings, and valuation assumptions. Analyst Commentary Recent research highlights a more constructive tone around Omnicell, with some analysts pointing to a potential cabinet replacement cycle and the Titan XT launch as key themes in their work.
Aggiornamento dell'analisi • Jan 06

OMCL: Future Medication Management Platform Rollout Will Support Balanced Risk Reward Profile

Analysts have lifted their price target on Omnicell from US$34 to US$43, pointing to updated assumptions for slightly lower discount rates, firmer revenue growth, improved profit margins, and a more moderate future P/E outlook. What's in the News Omnicell launched Omnicell Titan XT, an enterprise version of its automated dispensing systems designed to unify automation with its cloud-based OmniSphere medication management platform, aiming to create a connected, enterprise-wide medication management ecosystem across care areas.
Aggiornamento dell'analisi • Dec 18

OMCL: New Medication Management Platform Will Support Future Upside Potential

Analysts have raised their price target on Omnicell from approximately 47.33 dollars to 51.50 dollars. This change reflects slightly lower perceived risk, modestly stronger long term profit margins, and a higher expected future earnings multiple.
Aggiornamento dell'analisi • Dec 04

OMCL: Share Repurchases Will Support Future Upside Potential

Analysts have modestly raised their price target on Omnicell to approximately $47.33 per share, reflecting slightly lower perceived risk and stable, long-term growth and profitability expectations. What's in the News Updated fourth quarter 2025 revenue guidance to a range of $306 million to $316 million, signaling stable near term demand (company guidance).
Aggiornamento dell'analisi • Nov 20

OMCL: Share Repurchases And Executive Shifts Will Drive Future Upside

Analysts have revised their price target for Omnicell, lowering it modestly to $47.33 per share. This change reflects slight adjustments in key financial assumptions and uncertainty regarding future growth rates.
Articolo di analisi • Nov 13

Improved Revenues Required Before Omnicell, Inc. (NASDAQ:OMCL) Stock's 25% Jump Looks Justified

Omnicell, Inc. ( NASDAQ:OMCL ) shareholders would be excited to see that the share price has had a great month, posting...
Aggiornamento dell'analisi • Nov 06

OMCL: Share Repurchases And Leadership Transition Will Strengthen Market Position

Omnicell's analyst price target has been raised from $44 to approximately $47.33 per share. Analysts cite improved outlooks for revenue growth, profit margins, and lower discount rates as reasons supporting the upward revision.
Seeking Alpha • Jul 31

Omnicell Q2 Earnings: Market Ignoring The Segments

Summary Omnicell's service business is rapidly growing, now 22% of revenue, outpacing industry trends and supporting long-term upside. My updated DCF analysis yields a price target of $57.46, representing 93% upside, with Wall Street consensus trailing behind. The primary risk is the pace of transition from product to service revenue, but a strong backlog mitigates margin and cash flow concerns. Given robust service growth and healthy backlog, I maintain Omnicell at strong buy, seeing current volatility as a long-term buying opportunity. Read the full article on Seeking Alpha
Articolo di analisi • Jul 16

Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...
Articolo di analisi • Jun 28

Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, Omnicell fair value estimate is US$40.16 Omnicell is estimated...
User avatar
Nuova analisi • May 27

Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges

Supply chain improvements and near-shoring are expected to offset cost pressures, while a shift to recurring SaaS and services enhances earnings stability and valuation potential.
Articolo di analisi • May 14

It Looks Like Omnicell, Inc.'s (NASDAQ:OMCL) CEO May Expect Their Salary To Be Put Under The Microscope

Key Insights Omnicell's Annual General Meeting to take place on 21st of May CEO Randy Lipps' total compensation...
Articolo di analisi • May 09

US$38.50: That's What Analysts Think Omnicell, Inc. (NASDAQ:OMCL) Is Worth After Its Latest Results

There's been a notable change in appetite for Omnicell, Inc. ( NASDAQ:OMCL ) shares in the week since its first-quarter...
Articolo di analisi • Apr 07

Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Articolo di analisi • Mar 20

Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?

Omnicell, Inc. ( NASDAQ:OMCL ), is not the largest company out there, but it received a lot of attention from a...
Articolo di analisi • Feb 14

Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem

Despite posting healthy earnings, Omnicell, Inc.'s ( NASDAQ:OMCL ) stock has been quite weak. Our analysis suggests...
Seeking Alpha • Feb 12

Omnicell Q4 Earnings: Ignore The Short-Term Noise

Summary Omnicell's Q4 2024 earnings showed strong service revenue growth, despite soft overall revenue guidance, highlighting the service business as the key value driver. My updated DCF analysis yields a price target of $64.05, representing a 54% upside, and I raise my rating from buy to strong buy. The service business has grown from 6% to 22% of revenue since 2020, outpacing industry growth and improving margins, indicating long-term value. Downside risks include the need to balance service growth with product decline, but the healthy backlog mitigates these concerns, presenting a buying opportunity. Read the full article on Seeking Alpha
Articolo di analisi • Feb 09

Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

It's been a mediocre week for Omnicell, Inc. ( NASDAQ:OMCL ) shareholders, with the stock dropping 11% to US$40.16 in...
Articolo di analisi • Jan 28

Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate

Key Insights Omnicell's estimated fair value is US$59.79 based on 2 Stage Free Cash Flow to Equity Omnicell's US$44.35...
Articolo di analisi • Nov 27

Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues

With a price-to-sales (or "P/S") ratio of 2x Omnicell, Inc. ( NASDAQ:OMCL ) may be sending bullish signals at the...
Articolo di analisi • Nov 02

Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next

Shareholders will be ecstatic, with their stake up 23% over the past week following Omnicell, Inc. 's ( NASDAQ:OMCL...
Seeking Alpha • Nov 01

Omnicell Q3 Earnings: Look At The Growth Segment

Summary Omnicell, Inc. is a pharmacy management provider working towards the goal of an autonomous pharmacy. Q3 earnings looked weak on the surface with revenue and EBITDA down, but results by business show a strong and growing service business. Omnicell has unique technology with strong market tailwinds that support long-term growth. Read the full article on Seeking Alpha
Articolo di analisi • Oct 31

Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?

Omnicell, Inc. ( NASDAQ:OMCL ), is not the largest company out there, but it led the NASDAQGS gainers with a relatively...
Articolo di analisi • Oct 07

Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:OMCL - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20281,3837281N/A2
12/31/20271,3154672N/A8
12/31/20261,2473663N/A8
3/31/20261,2252095156N/A
12/31/20251,185267127N/A
9/30/20251,1782094153N/A
6/30/20251,1502389148N/A
3/31/20251,13621108164N/A
12/31/20241,11213135188N/A
9/30/20241,064-18118170N/A
6/30/20241,080-21152204N/A
3/31/20241,103-21165218N/A
12/31/20231,147-20126181N/A
9/30/20231,186-34165225N/A
6/30/20231,235-23127189N/A
3/31/20231,268-1848107N/A
12/31/20221,29661778N/A
9/30/20221,30948-555N/A
6/30/20221,258611877N/A
3/31/20221,1997298158N/A
12/31/20211,13278173232N/A
9/30/20211,07080195249N/A
6/30/202198760194242N/A
3/31/202191435164218N/A
12/31/202089232131186N/A
9/30/20208913886144N/A
6/30/202090649101164N/A
3/31/20209246985144N/A
12/31/201989761N/A145N/A
9/30/201986054N/A158N/A
6/30/201983648N/A117N/A
3/31/201980738N/A112N/A
12/31/201878738N/A104N/A
9/30/201877254N/A61N/A
6/30/201875448N/A27N/A
3/31/201874744N/A16N/A
12/31/201771331N/A25N/A
9/30/2017688-1N/A45N/A
6/30/2017678-6N/A72N/A
3/31/2017670-9N/A56N/A
12/31/201669610N/A50N/A
9/30/20166518N/A54N/A
6/30/201659914N/A40N/A
3/31/201653924N/A44N/A
12/31/201548531N/A38N/A
9/30/201547632N/A37N/A
6/30/201546332N/A50N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di OMCL ( 36.2% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di OMCL ( 36.2% all'anno) cresceranno più rapidamente del mercato US ( 16.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di OMCL cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di OMCL ( 4.3% all'anno) crescerà più lentamente rispetto al mercato US ( 11.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di OMCL ( 4.3% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di OMCL è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/11 10:13
Prezzo dell'azione a fine giornata2026/05/11 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Omnicell, Inc. è coperta da 20 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Raymond MyersBenchmark Company
William SutherlandBenchmark Company
Zhilin LongBerenberg